Figure 4.

Effect of single-agent targeted therapies in EML4:NTRK3 positive cell lines. The impact on cell viability of (A) entrectinib, (B) abemaciclib, (C) trametinib and (D) everolimus on the primary tumor (VBT247) and the 3rd recurrence under treatment with entrectinib (VBT363) was tested after 72 h incubation by ATP assay in triplicates. (E). The inhibitory effect is expressed as IC₅₀ values calculated from full dose–response curves (drug concentrations inducing a 50% reduction of the cell number in comparison to the untreated control cells).